iRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma
Open Access
- 2 July 2026
- journal article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 224, 107599
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Pudong New Area Health Commission (PWR12025-03)
This publication has 23 references indexed in Scilit:
- Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapyCancer Letters, 2025
- Peptide-drug conjugates: A new paradigm for targeted cancer therapyEuropean Journal of Medicinal Chemistry, 2024
- Cancer therapy with iRGD as a tumor-penetrating peptideBulletin du Cancer, 2023
- Malignant Glioma2023
- Transwell In Vitro Cell Migration and Invasion Assays2023
- An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapyBiomaterials, 2020
- Peptide chemistry toolbox – Transforming natural peptides into peptide therapeuticsBioorganic & Medicinal Chemistry, 2018
- Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic EfficacyCell Stem Cell, 2017
- Glioma Subclassifications and Their Clinical SignificanceNeurotherapeutics, 2017
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009